Halozyme Therapeutics, Inc. HALO
124.72 USD -5.62 (-4.31%)
Nov 5, 2026, 3:34 PM EST
124.28 Day range 131.44
61.23 52-week range 134.00
- YTD
- +85.32%
- 1 year
- +82.61%
News
zacks.com Halozyme Therapeutics (HALO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates Evaluate the expected performance of Halozyme Therapeutics (HALO) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of…
benzinga.com JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $79 JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $78 to $79.
zacks.com HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards? Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.
zacks.com These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
zacks.com Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
businesswire.com HALO-Flight Strengthens its Texas-based Air Med Fleet with Additional Bell 407GXi Purchase Order FORT WORTH, Texas--(BUSINESS WIRE)--AMTC-- Bell Textron Inc., a Textron Inc. (NYSE: TXT) company, announced during the annual Air Medical Transport Conference (AMTC) 2026 the purchase order for a…
fool.com Which Healthcare ETF Is the Better Buy: Invesco’s Broad RSPH or First Trust’s Biotech FBT? FBT has outperformed RSPH by a wide margin recently. The question is whether you want to own the fund that won last year or the one built to hold up over many years.
defenseworld.net 11,095 Halozyme Therapeutics, Inc. $HALO Shares Purchased by Gibbs Wealth Management Gibbs Wealth Management increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 140.0% in the undefined quarter, according to the company in its most recent Form 13F filing…
prnewswire.com Halozyme to Report Third Quarter 2026 Financial and Operating Results SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its third quarter 2026 financial and operating results on Thursday,…
zacks.com 5 Strong Buy Growth Stocks With High Margins to Grab Before Earnings Five Strong Buy stocks stand out ahead of earnings, combining high operating margins, revenue growth and exposure to AI, healthcare, energy and digital payments.
fxempire.com Halozyme's Strong Earnings Growth Sends Shares Higher Halozyme Therapeutics, Inc. (HALO) shares are up 910% since March 2014.
defenseworld.net Halozyme Therapeutics, Inc. $HALO Stock Position Cut by First Citizens Bank & Trust Co. First Citizens Bank and Trust Co. decreased its position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 59.5% during the undefined quarter, according to its most recent filing with the Securities…
zacks.com 5 Stocks to Buy Using the Relative Price Strength Strategy HALO, GCT, LIND, PR and CVX stand out as relative strength picks amid market volatility, backed by strong price performance and upbeat earnings estimates.
zacks.com Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.
zacks.com 3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
benzinga.com Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today The Nasdaq 100 fell 1% by midday Wednesday after September CPI topped forecasts, pushing Treasury yields and rate-hike bets higher.
benzinga.com Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.
zacks.com Why Investors Need to Take Advantage of These 2 Medical Stocks Now The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
zacks.com Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
benzinga.com TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130 TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $105 to $130.
benzinga.com Here's How Much $100 Invested In Halozyme Therapeutics 5 Years Ago Would Be Worth Today Halozyme Therapeutics (NASDAQ:HALO) has outperformed the market over the past 5 years by 12.8% on an annualized basis producing an average annual return of 24.48%. Currently, Halozyme Therapeutics…
defenseworld.net Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,191,600.00 in Stock Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average…
defenseworld.net Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,188,000.00 in Stock Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the business's stock in a transaction dated Thursday, October 8th. The stock was sold at an average…
benzinga.com JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $78 JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $70 to $78.
zacks.com HALO Wins Court Order Blocking Merck's Keytruda SC in Europe Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.- benzinga.com HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $115 to $130.
zacks.com HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.- benzinga.com Halozyme Therapeutic Expands Collaboration, License Deal With Argenx Over Development, Commercialization Of ENHANCE With Two Additional Targets Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize
benzinga.com $1000 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth This Much Today Halozyme Therapeutics (NASDAQ:HALO) has outperformed the market over the past 15 years by 8.16% on an annualized basis producing an average annual return of 21.6%. Currently, Halozyme Therapeutics…
benzinga.com Halozyme Therapeutics Announces Proposed $1.05B Convertible Senior Notes Offering Due 2033 Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $115 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $115 price target.
benzinga.com Top 3 Health Care Stocks That May Implode In August 3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.- benzinga.com Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110 Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market Perform to Outperform and raises the price target from $83 to $110.
- benzinga.com TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105 TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $96 to $105.
benzinga.com Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 results and raised FY26 sales guidance. Other big gains include DOCS, QNST, TEAM, CRSR, OABI, PUBM, TWLO,…- benzinga.com Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $93 Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $92 to $93.
- benzinga.com Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $95 Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Equal-Weight and raises the price target from $75 to $95.
benzinga.com Atlassian To Rally More Than 63%? Here Are 10 Top Analyst Forecasts For Friday Wall Street analysts changed ratings & price targets for top stocks. Check out all changes including upgrades & downgrades on Benzinga analyst ratings page.- benzinga.com HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $115 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $95 to $115.
benzinga.com Halozyme Therapeutics Q2 Adj. EPS $2.28 Beats $1.84 Estimate, Sales $480.999M Beat $407.493M Estimate Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $2.28 per share which beat the analyst consensus estimate of $1.84 by 23.91 percent. This is a 48.05 percent increase over earnings…- benzinga.com Halozyme Therapeutics Raises FY2026 Adj EPS Guidance from $7.75-$8.25 to $8.65-$9.00 vs $8.14 Est; Raises FY2026 Sales Guidance from $1.710B-$1.810B to $1.835B-$1.910B vs $1.773B Est Halozyme Therapeutics (NASDAQ:HALO) raises FY2026 Adj EPS guidance from $7.75-$8.25 to $8.65-$9.00 vs $8.14 analyst estimate. Raises FY2026 sales outlook from $1.710 billion-$1.810 billion to $1.835…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $95 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $95 price target.
benzinga.com Halozyme Therapeutics Signs Agreement With Incyte To Mull Additional Subcutaneous Formulations Of INCA033989 Mutant Calreticulin-Targeted Monoclonal Antibody Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to evaluate
benzinga.com Halozyme Sees Little Royalty Impact From Medicare Drug Pricing Rule, Says CMS Proposal Should Not Hurt ENHANZE Partnerships Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for…
benzinga.com Earnings Scheduled For May 11, 2026 - benzinga.com Halozyme Therapeutics Signs License Agreement With GSK For ENHANZE Drug Delivery Technology To Develop, Commercialize Subcutaneous Administration Of Multiple Oncology Targets Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced the Company entered into a global collaboration and license agreement with GSK. Under the collaboration, GSK…
benzinga.com Tech Stocks Rebound, Crude Rallies Above $64 On Iran Tensions: What's Moving Markets Wednesday? Tech stocks recovered on Wednesday, led by a rally in battered software names, as the Nasdaq 100 jumped 1.4% past 25,000, outpacing the S&P 500's 1% gain and the Dow's 0.7% advance.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Earnings Scheduled For February 17, 2026